Monopar Therapeutics MNPR Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's accretion (amortization) of discounts and premiums, investments?
- Monopar Therapeutics (MNPR) reported accretion (amortization) of discounts and premiums, investments of $799.63K in Q1 2026.
- How has Monopar Therapeutics's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Monopar Therapeutics's accretion (amortization) of discounts and premiums, investments increased by 569.1% year-over-year, from $119.51K to $799.63K.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This metric reflects the non-cash adjustments to the carrying value of investment securities held by the company, resulting from the amortization of premiums or accretion of discounts. It bridges the gap between the purchase price of financial instruments and their face value over time. This adjustment is necessary to reconcile net income with actual cash flows generated from investment activities.